Ketosis, Immune Function and Metabolic Adaptation in Response to Short-term Fasting in Critical Illness (KETO-FAST)
KETOsis, Immune Function and Metabolic Adaptation in Response to Short-Term Fasting in Critical Illness (KETO-FAST): A Translational Substudy of the FAST-ICU Cluster-randomized Cross-over Trial.
KETO-FAST is a pre-planned translational substudy of the FAST-ICU cluster-randomized cross-over trial. The substudy will characterize ketone body production and associated metabolic, autophagy-related, and immune cellular responses during the first 72 hours after intensive care unit admission in critically ill patients exposed to delayed nutrition compared with patients receiving standard care.
Patients enrolled in FAST-ICU at designated participating centers will undergo serial blood sampling during the first 72 hours after ICU admission. Plasma ketone body concentrations, targeted metabolomics, serum-induced cellular responses in vitro, leukocyte autophagy markers, and immune cell phenotypes and functional markers will be assessed. In addition, 10 healthy volunteers will perform a 72-hour fast with blood sampling to provide reference values from non-critically ill subjects.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Early nutrition during critical illness remains controversial. Large randomized trials in intensive care unit patients have found no clear benefit and possible harm from full early feeding, while current guidelines recommend early hypocaloric nutrition. However, high-quality evidence comparing early hypocaloric nutrition with complete withholding of nutrition during the first days of critical illness is limited.
In healthy humans, short-term starvation induces ketone body production through fatty acid oxidation. Ketone bodies such as β-hydroxybutyrate and acetoacetate are energy substrates for organs including the heart and brain and may also act as signaling molecules involved in autophagy, mitochondrial metabolism, and immune function. In critical illness, however, the normal fasting response may be altered by stress metabolism, inflammation, insulin administration, corticosteroids, and organ dysfunction. The extent to which critically ill patients develop clinically relevant ketosis during short-term fasting remains uncertain.
The parent FAST-ICU trial is a cluster-randomized cross-over trial comparing two ICU nutrition strategies during the first 72 hours after ICU admission: delayed nutrition with no enteral or parenteral nutrition and no glucose-containing maintenance fluids, versus standard care including early enteral nutrition and maintenance glucose according to local practice. KETO-FAST uses this randomized exposure to study the biological response to short-term fasting in critically ill patients.
The primary objective of KETO-FAST is to compare plasma ketone body concentrations during the first 72 hours after ICU admission between patients exposed to delayed nutrition and patients receiving standard care. Secondary and exploratory objectives are to characterize associated changes in targeted metabolic pathways, serum-mediated cellular responses, leukocyte autophagy markers, and immune cell phenotypes and functional markers.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Martin Sundström Rehal, MD PhD
- Número de telefone: +46-8-12381507
- E-mail: martin.sundstrom-rehal@regionstockholm.se
Locais de estudo
-
-
-
Stockholm, Suécia, 14186
- Karolinska University Hospital Huddinge
-
Contato:
- Martin Sundström Rehal, MD PhD
- Número de telefone: +46812381507
- E-mail: martin.sundstrom-rehal@regionstockholm.se
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adult (≥18 years).
- ICU admission (index admission to the participating ICU).
Exclusion Criteria:
- The patient requires intravenous glucose infusion, enteral nutrition or parenteral nutrition according to the attending clinician's assessment,
- Acute or acute-on-chronic liver failure
- Moderate hypernatremia ( >150 mmol/L)
- Diabetic ketoacidosis or hyperosmolar hyperglycemic state at admission,
- Pregnancy,
- Exclusive end-of-life care (no other treatment goal than comfort care for end of life),
- Organ donor,
- Prior enrolment in this trial during the same hospitalisation,
- Patients with a metabolic disease requiring specific diet and patients with clinical need for a ketogenic diet.
- Patients already enrolled in other interventional studies on nutrition, intravenous fluids, phosphate supplementation or hormonal therapies that influence glucose homeostasis.
- Inclusion not possible due to site-specific regulatory issues regarding the ethical approval or informed consent procedure.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Intervention
Intensive care unit patients with policy allocation to delayed medical nutrition therapy in main study: no enteral nutrition, parenteral nutrition or maintenance glucose solutions for first 72 hours.
|
Intervention Policy (A): Withhold nutrition and glucose solutions (First 72 h)
|
|
Comparador Ativo: Control
Intensive care unit patients with policy allocation to standard care in main study: nutritional management according to regular unit protocols.
|
Control Policy (B): Standard of Care
|
|
Comparador Ativo: Healthy reference controls
Healthy subjects undergoing 72 hour fast with same blood sampling procedure as in ICU.
|
72-hour fasting period with water and non-caloric beverages.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-group differences over time in plasma β-hydroxybutyrate and acetoacetate concentrations during the first 72 hours after ICU admission
Prazo: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Plasma β-hydroxybutyrate and acetoacetate concentrations will be measured in mmol/L in serial blood samples collected from ICU admission through 72 hours after admission.
Cumulative concentrations of ketone bodies will be compared between the delayed-nutrition and standard-care groups over the measurement period.
Results will be reported as between-group effect estimates over time, with 95% confidence intervals.
|
From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-group difference in serum-induced autophagy flux in cultured cells
Prazo: Single serum sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
Cultured cells will be incubated with serum collected from substudy participants.
Autophagy flux will be quantified using prespecified cellular autophagy markers under paired conditions with and without pharmacological inhibition of lysosomal degradation.
The resulting normalized autophagy-flux measure will be compared between the delayed-nutrition and standard-care groups and reported as a between-group effect estimate with a 95% confidence interval.
|
Single serum sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
|
Between-group difference in normalized relative abundance of autophagy-related proteins in peripheral blood leukocytes assessed by Western blotting
Prazo: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
The relative abundance of prespecified autophagy-related proteins will be quantified in isolated peripheral blood leukocytes by Western blot densitometry and normalized to an appropriate loading control.
For each protein marker, and for derived protein ratios where applicable, normalized values will be compared between the randomized groups and reported as a between-group effect estimate with a 95% confidence interval.
|
Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
|
Between-group differences in frequencies of major peripheral blood immune-cell subsets assessed by multiparameter flow cytometry
Prazo: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
Multiparameter flow cytometry will be used to identify and quantify prespecified major immune-cell populations and phenotypic subsets relevant to critical illness and nutrient deprivation.
Each subset will primarily be expressed as a percentage of its relevant parent cell population.
Subset frequencies will be compared between the delayed-nutrition and standard-care groups and reported as between-group effect estimates with 95% confidence intervals.
|
Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
|
Between-group differences in immune-cell phenotypes and marker expression assessed by multiparameter flow cytometry
Prazo: Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
Prespecified peripheral blood immune-cell populations will be characterized by multiparameter flow cytometry.
Outcomes will include the frequency of cell populations expressing markers related to immune activation, exhaustion or immune-checkpoint signalling, cellular metabolic state, and functional capacity, together with marker-expression intensity where applicable.
Results for each prespecified cell population and marker will be compared between the delayed-nutrition and standard-care groups and reported as between-group effect estimates with 95% confidence intervals.
|
Single final substudy sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
|
Between-group difference in normalized expression of prespecified autophagy-related genes in peripheral whole blood on ICU day 3 or 4, assessed by RNA sequencing
Prazo: Single blood sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
RNA will be extracted from peripheral whole blood collected in EDTA tubes on ICU day 3 or 4. Expression of prespecified autophagy-related genes will be quantified using RNA sequencing and compared between the randomized groups.
For each gene, the treatment effect will be reported as the between-group log2 fold change with a 95% confidence interval and a false-discovery-rate-adjusted P value.
|
Single blood sample collected on ICU day 3 or 4, depending on the time of ICU admission
|
|
Between-group differences in plasma concentrations of prespecified metabolites and pathway-level metabolomic measures during the first 72 hours after ICU admission
Prazo: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Targeted metabolomic analysis will quantify prespecified plasma metabolites related to metabolic pathways relevant to fasting and critical illness, including ketogenesis, fatty acid metabolism, amino acid metabolism, glycolysis, and the tricarboxylic acid cycle.
Individual metabolite concentrations and predefined pathway-level summary measures, where applicable, will be compared between the delayed-nutrition and standard-care groups across the first 72 hours after ICU admission.
Results will be reported as between-group effect estimates with 95% confidence intervals.
|
From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Between-group differences in point-of-care whole-blood β-hydroxybutyrate concentration during the first 72 hours after ICU admission
Prazo: From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Whole-blood β-hydroxybutyrate concentration will be measured in mmol/L using a point-of-care ketone analyzer at participating sites where this measurement is available.
Measurements obtained from ICU admission through 72 hours will be compared between the delayed-nutrition and standard-care groups.
Results will be reported for individual sampling time points and as an overall between-group effect across the measurement period, with 95% confidence intervals.
|
From ICU admission and up to 72 hours after ICU admission, using serial daily blood samples
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Cadeira de estudo: Olav Rooyackers, PhD, Karolinska University Hospital/Karolinska Institute
- Investigador principal: Martin Sundström Rehal, MD PhD, Karolinska University Hospital/Karolinska Institutet
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- K 2026-5194
- ISRCTN16339579 (Identificador de registro: ISRCTN)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .